Posted by Michael Wonder on 20 May 2020
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
20 May 2020 - Only PARP inhibitor to improve overall survival versus enzalutamide or abiraterone in a biomarker-based subset of prostate cancer patients with BRCA1/2 or ATM mutations.
AstraZeneca and MSD today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
The approval by the US FDA was based on results from the Phase III PROfound trial, which were published in The New England Journal of Medicine.
